Alloy Pricing Analysis & Total Cost: What You Actually Pay for Menopause HRT

How Alloy's Pricing Model Works

Alloy operates as a direct-to-consumer telehealth platform focused exclusively on menopause and perimenopause care. There is no upfront consultation fee. You complete an online health questionnaire, a licensed provider reviews it, and if clinically appropriate, a prescription is written and shipped to your door. Revenue comes from medication sales rather than visit charges.

This model mirrors what the North American Menopause Society (NAMS) 2022 Position Statement describes as a growing trend: telehealth-delivered HRT designed to close the "menopause care gap." NAMS estimates that only about 1 in 4 women who could benefit from hormone therapy actually receives it [1]. Part of the barrier is cost transparency. Alloy's no-consultation-fee approach removes one layer of that barrier, but the medication prices themselves deserve scrutiny.

Each medication is priced individually. A woman using estradiol patches alone might pay $35 per month. Add oral micronized progesterone and the bill rises to $60 to $80. Add compounded testosterone cream and you can reach $130 to $150. Alloy bundles some products at a small discount, but most combinations are priced à la carte. Shipping is included in most orders, though expedited delivery carries a surcharge.

One detail worth noting: Alloy does not accept insurance. Every dollar comes out of pocket. For women whose commercial insurance covers generic estradiol and progesterone with a $10 to $15 copay, the math may favor a traditional provider visit plus pharmacy pickup, even with a $50 specialist copay factored in.

What Does Alloy Prescribe?

Alloy's formulary centers on FDA-approved hormone therapy products, supplemented by compounded options where branded equivalents are expensive or unavailable. The core prescriptions include transdermal estradiol (patches and creams), oral micronized progesterone (the bioidentical form used in the KEEPS trial and recommended by the Endocrine Society's 2015 guidelines), and compounded testosterone cream [2][3].

The KEEPS trial (Kronos Early Estrogen Prevention Study, N=727) demonstrated that oral micronized progesterone combined with low-dose transdermal estradiol was well-tolerated in recently menopausal women over 4 years, with no significant increase in cardiovascular events compared to placebo [2]. This regimen forms the backbone of what Alloy prescribes.

Beyond hormones, Alloy sells non-prescription products: vaginal moisturizers, supplements, and skincare items marketed toward menopausal women. These carry separate price tags, typically $15 to $40 per item. They are optional, but the platform promotes them during checkout. A woman who adds two or three of these products alongside her prescriptions could see monthly totals approach $200.

Dr. Stephanie Faubion, Medical Director of NAMS, has stated: "The most effective treatment for bothersome vasomotor symptoms remains hormone therapy, and the benefits generally outweigh the risks for healthy women under 60 or within 10 years of menopause onset" [1]. Alloy's prescribing patterns align with this guidance, which is a point in the platform's favor from a clinical standpoint.

Alloy vs. Alternatives: Price Comparison

Comparing D2C menopause platforms requires standardizing the comparison. The table below uses a common regimen: transdermal estradiol plus oral micronized progesterone, the combination NAMS and the Endocrine Society both endorse as first-line for symptomatic menopausal women with an intact uterus [1][3].

For this two-drug regimen, Alloy's estimated monthly cost falls between $60 and $90. Evernow, another D2C menopause platform, charges a $35 monthly membership plus medication costs that start around $30, putting the total in a similar $65 to $100 range. Midi Health charges per visit ($250 for initial, $95 for follow-up) but can route prescriptions to a patient's insurance pharmacy, potentially lowering the medication cost to a $10 to $20 copay. Winona prices similarly to Alloy at $60 to $100 monthly for a two-drug regimen.

The meaningful differentiator is not the sticker price on the medication. It is total annual cost, which includes visits, labs, and add-ons. A woman using Alloy for estradiol plus progesterone for 12 months pays roughly $720 to $1 to 080 in medication alone. If she orders the recommended baseline labs (lipid panel, metabolic panel, and possibly estradiol/FSH levels) through a third-party lab service because Alloy does not include labs, add $150 to $300. Total: $870 to $1,380 per year.

Compare that to a traditional OB-GYN visit with insurance. Two annual visits at $50 copay each ($100), plus generic estradiol patches and progesterone capsules at $15/month ($180/year), plus labs covered by insurance ($0 to $50). Total: $280 to $330 per year. The convenience premium for Alloy can exceed $600 annually.

Is Alloy Legit? Clinical and Regulatory Standing

Alloy operates legally as a telehealth platform. Prescriptions are written by licensed providers in the patient's state. The hormones prescribed are either FDA-approved generics or compounded by licensed pharmacies. This is a legitimate medical service, not a gray-market supplement shop.

The clinical foundation is sound. The 2017 Endocrine Society Clinical Practice Guideline on menopausal hormone therapy recommends transdermal estradiol as the preferred route for most women, particularly those with elevated cardiovascular or thromboembolic risk [3]. Alloy defaults to transdermal delivery. The WHI estrogen-alone trial (N=10,739) showed that conjugated equine estrogens in women aged 50 to 59 did not increase coronary heart disease risk over 7.2 years of follow-up, and the more recent WHI 18-year cumulative follow-up confirmed no long-term increase in all-cause mortality for either estrogen-alone or estrogen-plus-progestin arms [4][5].

Where skepticism is warranted: Alloy's compounded testosterone cream. The FDA has not approved testosterone therapy for women, and the Endocrine Society's 2019 position statement on testosterone therapy for women supports short-term use only for hypoactive sexual desire disorder (HSDD) in postmenopausal women, at doses approximating premenopausal physiologic levels [6][7]. Alloy does prescribe testosterone for this indication, but women should understand that this use is off-label in the United States and that long-term safety data beyond 24 months are limited.

Dr. Susan Davis, lead author of the 2019 global consensus position on testosterone therapy for women, has stated: "We recommend testosterone therapy only for postmenopausal women with HSDD after formal assessment, and only at doses that approximate premenopausal concentrations" [6]. Any platform prescribing testosterone to women should adhere to these boundaries.

Breaking Down the Real Monthly Bill

A realistic cost scenario helps more than a price list. Consider a 52-year-old woman, 3 years postmenopausal, experiencing moderate hot flashes and vaginal dryness. Her provider through Alloy prescribes estradiol patches 0.05 mg twice weekly and oral micronized progesterone 100 mg nightly.

Her monthly Alloy bill: estradiol patches at approximately $40 plus progesterone at approximately $30. That is $70 per month, $840 per year. She adds Alloy's vaginal moisturizer ($28/month), bringing the monthly total to $98. Over 12 months, she spends $1,176.

Now she mentions low libido. Her provider adds compounded testosterone cream at $65/month. Monthly total: $163. Annual total: $1,956. Add labs ordered through an outside service ($200/year), and her all-in annual spend reaches $2,156.

This is not unreasonable for cash-pay telehealth, but it is substantially more than what the same regimen would cost through an insurance-based provider. Generic estradiol patches carry a wholesale acquisition cost (WAC) of roughly $30 to $60 for a 30-day supply, and generic progesterone capsules run $8 to $15 at retail pharmacies with a GoodRx coupon [8]. The convenience, speed, and menopause-specialized care that Alloy offers come at a tangible premium.

Who Gets the Most Value from Alloy?

Alloy fits a specific profile best. Women without insurance, or whose insurance does not cover HRT, eliminate the traditional-route cost advantage. Women in states with limited menopause-trained providers gain access they otherwise lack. The NAMS 2022 Position Statement estimated that only 20% of OB-GYN residency programs provide menopause-specific training [1]. That means many women's local providers may lack confidence prescribing HRT, creating a real gap Alloy helps fill.

Women who already have good insurance coverage and a knowledgeable provider may find Alloy's pricing hard to justify. The same FDA-approved medications are available at any retail pharmacy, and a single annual gynecology visit with a menopause-competent clinician provides the oversight that telehealth questionnaires may not fully replicate.

One area where D2C platforms including Alloy face legitimate criticism: longitudinal monitoring. The Endocrine Society guidelines recommend annual reassessment of hormone therapy, including discussion of ongoing benefits versus risks, and periodic attempts at dose reduction or discontinuation [3]. The asynchronous telehealth model can make this ongoing clinical relationship thinner than an in-person one, though Alloy does offer follow-up messaging with providers.

Hidden Costs and What the Sticker Price Misses

Three costs that Alloy's website does not prominently display deserve attention.

First, lab work. Baseline and follow-up labs are standard of care for women starting HRT. The American College of Obstetricians and Gynecologists (ACOG) recommends screening for contraindications before initiating therapy, including assessing lipids and liver function in women with relevant risk factors [9]. Alloy does not bundle labs into its pricing. Third-party lab orders through services like Quest or Labcorp can cost $100 to $300 per panel without insurance.

Second, dose adjustments. If a woman's initial estradiol dose is insufficient and her provider increases the patch strength from 0.05 mg to 0.075 mg or switches to a higher-cost formulation, monthly medication costs increase. Alloy's pricing tiers reflect this: higher doses and branded products cost more.

Third, the non-prescription upsells. Alloy's marketplace includes supplements (calcium, vitamin D, omega-3), skincare, and wellness products. While optional, the checkout experience promotes them. A woman who adds two supplements at $25 each bumps her monthly spend by $50 without any prescription-level clinical evidence for most of these products. The USPSTF found insufficient evidence to recommend calcium and vitamin D supplementation for fracture prevention in community-dwelling postmenopausal women, giving the combination a grade D recommendation for doses at or below 400 IU vitamin D and 1 to 000 mg calcium [10].

Alloy Reviews: What Users Report

User reviews across independent platforms (Trustpilot, Reddit, and app store listings) cluster around several themes. Positive reviews highlight the convenience of home delivery, the speed of receiving a prescription (often within 48 hours), and the menopause-specific focus that general telehealth platforms lack. Negative reviews most frequently cite pricing (described as "expensive for generics"), difficulty reaching providers for follow-up questions, and frustration with subscription auto-renewals.

A recurring concern in negative reviews involves the compounded products. Some users report inconsistent texture or dosing of compounded testosterone cream, which reflects a known limitation of compounded medications generally rather than an Alloy-specific quality issue. The FDA has noted that compounded drugs are not evaluated for safety, efficacy, or manufacturing consistency the way FDA-approved drugs are [11].

No large-scale, independent clinical outcomes study of Alloy's patient population has been published. The clinical evidence supporting HRT for menopause symptom relief is strong regardless of the dispensing platform, with the Cochrane Database review of HRT for vasomotor symptoms (N=24,417 across 24 trials) showing a 75% reduction in hot flash frequency and 87% reduction in severity with estrogen-based therapy versus placebo [12]. But whether Alloy's specific model of care produces adherence and outcomes comparable to traditional practice is an unanswered question.